ESTRO 2024 - Abstract Book

S1142

Clinical - Haematology

ESTRO 2024

Forty-seven complete answers were collected from 51 EORTC investigators from 19 countries specializing in cutaneous lymphoma treatment. Thirty investigators (64%) treat 1- 99, and 17 (36%) treat ≥100 cutaneous lymphoma patients per year. The radiation doses were highly heterogeneous and range between 4 and 60 Gy ( Figure 1 ). Patients with mycosis fungoides (MF), primary cutaneous anaplastic large cell lymphoma (pcALCL), and indolent cutaneous B cell lymphoma (CBCL) are treated with hypofractionated regimens in 34%, 26%, and 34% of treatment centers, respectively. Conventional fractionated radiotherapy is considered to be the standard of care for patients with primary cutaneous diffuse large B-cell lymphom (DLBCL) across all centers. The proportion of low dose regimens at the participating centers was 23% for MF, 11% for pcALCL, and 25% for indolent CBCL. The proportions of radiation centers applying high radiation doses are listed in table 1. Only 20 (42%) investigators have total skin electron beam therapy (TSEBT) expertise and access to this technique. Of these, 25% of responders apply hypofractionated concepts (8-12 Gy in a 4 Gy fraction per week). Nearly half of the investigators (12/27) who do not have TSEBT expertise would like to establish the technique at their institutions.

Figure 1: Radiation dose recommendations from 47 investigators specializing in cutaneous lymphoma treatment

Table 1: The proportions of radiation centers applying high radiation doses according to fractionation regimens and histologic entities* .

* Based on the recent radiotherapy data and international guidelines

MF: Mycosis fungoides, TSBET : total skin electron beam therapy, pcALCL : primary cutaneous anaplastic large cell lymphoma, MZL : Marginal zone lymphoma, FL : follicular lymphoma, DLBCL : Primary cutaneous diffuse large B-cell lymphoma